CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BCG vaccineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (6)

Name (Synonyms) Correlation
drug711 Isotonic saline 0.9% Wiki 0.71
drug681 Inhaled sedation Wiki 0.71
drug1061 Povidone-Iodine 0.5% Wiki 0.71
drug708 Intravenous sedation Wiki 0.71
drug1062 Povidone-Iodine 2% Wiki 0.71
drug1016 Placebo Wiki 0.11

Correlated MeSH Terms (12)

Name (Synonyms) Correlation
D006331 Heart Diseases NIH 0.50
D003327 Coronary Disease NIH 0.41
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.35
D008173 Lung Diseases, Obstructive NIH 0.29
D014777 Virus Diseases NIH 0.09
D013577 Syndrome NIH 0.09
D055371 Acute Lung Injury NIH 0.08
D012127 Respiratory Distress Syndrome, Newborn NIH 0.08
D012128 Respiratory Distress Syndrome, Adult NIH 0.07
D007239 Infection NIH 0.05
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial

Based on findings of the interim analysis of the ACTIVATE study showing 53% decrease of the incidence of all new infections with BCG vaccination, a new trial is designed aiming to validate if BCG can protect against COVID-19 (Corona Virus Disease-19).The aim of the study is to demonstrate in a double-blind, placebo-controlled approach if vaccination of participants susceptible to COVID-19 with BCG vaccine may modulate their disease susceptibility for COVID-19. This will be validated using both clinical and immunological criteria.

NCT04414267 COVID-19 Virus Diseases Corona Virus Infection Coronary Heart Disease Chronic Obstructive Pulmonary Disease Biological: BCG vaccine Biological: Placebo
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Heart Diseases Coronary Disease Virus Diseases
HPO:Chronic obstructive pulmonary disease Obstructive lung disease

Primary Outcomes

Description: This is set on visit 3 (90 ± 5 days from the date of visit 1). The two groups of vaccination are compared for the primary endpoints which is composite. Patients who meet any of the following will be considered to meet the primary endpoint: Positive for the respiratory questionnaire endpoint when at least one of the following combination is met either at visit 2 and/or at visit 3: One situation definitively related to COVID-19 All four questions of symptoms possibly related to COVID-19 At least two questions of symptoms possibly related to COVID-19 as well as need for admission at the emergency department of any hospital and/or need for intake of antibiotics At least four questions of symptoms probably related to COVID-19 one of which is "need for admission at the emergency department of any hospital and/or need for intake of antibiotics" Positive IgG or IgM antibodies against SARS-CoV-2

Measure: Positive for the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 3.

Time: Visit 3 (90 +/- 5 days)

Secondary Outcomes

Description: The two groups of vaccination are compared for the primary endpoints which is composite (as defined at primary study endpoint) and meet a positive respiratory questionnaire endpoint on visit 4

Measure: Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 4

Time: Visit 4 (135 +/- 5 days)

Description: The two groups of vaccination are compared for the primary endpoints which is composite (as defined at primary study endpoint) and meet a positive respiratory questionnaire endpoint (as defined at primary study endpoint) on visit 5

Measure: Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 5

Time: Visit 5 (180 +/- 5 days)

Description: Prevalence of IgG/IgM against SARS-CoV-2 will be measured among the patients who failed the eligibility procedure and the patients that were eligible and were enrolled

Measure: Prevalence of IgG/IgM against SARS-CoV-2

Time: Screening Visit and Visit 3 (90 +/- 5 days)

Description: Itemized analysis of each of the components of the respiratory questionnaire on each study visit

Measure: Analysis of each of the components of the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19.

Time: Visit 2 (45 +/- 5 days), Visit 3 (90 +/- 5 days), Visit 4 (135 +/- 5 days), Visit 5 (180 +/- 5 days)

2 Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial

Bacillus Calmette-Guérin (BCG) vaccine not only protects against tuberculosis, but has also been shown to induce protection against various infections with a viral aetiology, leading to significant reductions in morbidity and mortality. We hypothesize that BCG vaccination might be a potent preventive measure against SARS-CoV-2 infection and/or may reduce disease severity in elderly people, who are known to be at increased risk of illness and death from SARS-CoV-2 infection. Therefore, we will in this placebo-controlled adaptive multi-centre randomized controlled trial evaluate the ability of BCG to reduce hospital admission and its efficacy to improve the clinical course of SARS-CoV-2 infection in elderly people((≥ 60 years of age).

NCT04417335 COVID-19 Biological: BCG vaccine Biological: Placebo

Primary Outcomes

Measure: SARS-CoV-2 related hospital admission

Time: Maximum of 1 year

Secondary Outcomes

Measure: the duration of hospital admission due to documented COVID-19

Time: Maximum of 1 year

Measure: the cumulative incidence of documented SARS-CoV-2 infection

Time: Maximum of 1 year

Measure: the cumulative incidence of self-reported acute respiratory symptoms or fever

Time: Maximum of 1 year

Measure: the cumulative incidence of death due to documented SARS-CoV-2 infection

Time: 1 year

Measure: the cumulative incidence of hospital admission for any reason

Time: Maximum of 1 year

Measure: the cumulative incidence of Intensive Care Admission due to documented SARS-CoV-2 infection

Time: Maximum of 1 year

Related HPO nodes (Using clinical trials)

HP:0006510: Chronic obstructive pulmonary disease
Genes 30
NCF4 GP1BB PTPN22 GLA ARVCF WAS NFKB1 UFD1 WIPF1 CYBB RREB1 NCF1 CYBC1 HLA-DPA1 DNAAF4 SERPINA1 CTLA4 PRTN3 CYBA TBX1 HMOX1 SEC24C MMP1 HLA-DPB1 TBX1 JMJD1C MYH7 COMT HIRA NCF2
Protein Mutations 2
A118G G551D
SNP 6
rs1051730 rs1800470 rs1828591 rs25331 rs4129267 rs7103572
HP:0006536: Obstructive lung disease
Genes 84
CCDC103 CFAP221 SCNN1B PTPN22 GLA DNAAF6 DNAAF5 SCNN1A TTC25 CCDC39 NME8 DNAAF2 CFTR UFD1 DNAAF4 OFD1 CCDC151 FOXJ1 RSPH4A CYBB ZMYND10 RREB1 HLA-DPA1 CCNO GLA SERPINA1 VPS33A LRRC56 MMP1 APC RSPH1 HLA-DPB1 JMJD1C MYH7 COMT DNAH11 DNAI2 LRRC6 NCF4 GP1BB CCDC114 SPAG1 ARVCF DRC1 WAS NFKB1 STK36 MGP HYDIN WIPF1 GAS8 DNAAF3 DNAH9 NCF1 CYBC1 RSPH9 ARMC4 DNAAF4 MCIDAS DNASE1L3 RPGR DNAH5 CTLA4 PRTN3 CYBA DNAL1 CFAP298 TBX1 HMOX1 CCDC40 CFAP300 SEC24C DNAH1 DNAI1 DNAAF1 SCNN1G TBX1 SPEF2 RSPH3 GAS2L2 HIRA DNAJB13 CCDC65 NCF2
Protein Mutations 2
A118G G551D
SNP 6
rs1051730 rs1800470 rs1828591 rs25331 rs4129267 rs7103572